Poxel Secures Additional Financing Through New Tranche D PDR Bonds

Poxel SA, a biopharmaceutical company, announced on March 25, 2026, the signing of the new Tranche D PDR subscription agreement with IPF Partners. This agreement secures €3.75 million in financing as part of Poxel's court-approved continuation plan. The company has already issued €0.5 million of these bonds, with another €0.5 million set for release on March 26, 2026.

The terms validated by the Lyon Commercial Court provide a cash interest rate of 0%, a capitalized interest rate of 35%, and a 13.7% exit fee. The Twymeeg royalties are allocated 90% towards repaying the bond. The bonds are issued subject to sales target achievements for Imeglimin, and early redemption clauses apply under certain conditions.

The Tranche D PDR aims to stabilize Poxel's financial operations, complemented by potential additional financing and cost reduction strategies. The availability period extends to the fifth anniversary of the plan's adoption.